Myelodysplastic Syndromes
Low-dose topotecan in myelodysplastic syndromes has no effect
Published in Blood Weekly, March 11th, 2004
According to their study, "Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2 mg/m2 i.v. daily for 5 days as a continuous infusion limits its use in older patients."
"Therefore, we studied topotecan 1.5 mg/m2 per day i.v. over 2 h for 3 consecutive days in 20 patients with high-risk MDS (12 RAEB; 4 RAEB-T; 4 CMMoL)," wrote D.A. Vaena and colleagues, Indiana University, Division of Hematology & Oncology.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2004-03-11)
More Articles from Blood Weekly
- Biotechnology
Autologous fibrin glue useful for maxillofacial surgery - Stem-Cell Transplantation
Rituximab effective against post-SCT autoimmune hemolytic anemia - Cardiovascular Disease
Stem-cell transplantation can prevent lysosomal storage disease-induced CVD - HIV/AIDS Vertical Transmission
Novel DNA extraction method enables HIV diagnosis via dried blood - Leukemia Therapy
SCT with voriconazole treatment feasible for AML with pulmonary aspergillosis - Stem-Cell Transplantation
Minisequencing useful for SNP analysis - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
